Evidence map›Paper›PMID 31962372›Full record

SynthesisCancer medicine2020

Prognostic factors of adjuvant chemotherapy discontinuation among stage III colon cancer patients: A survey of medical oncologists and a systematic review and meta-analysis.

Devon J Boyne, Dylan E O'Sullivan, Emily V Heer, Robert J Hilsden, Tolulope T Sajobi, Winson Y Cheung, Darren R Brenner, Christine M Friedenreich

Abstract readMeta-AnalysisSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Cancer medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Devon J BoyneDepartment of Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.ORCID 0000-0001-6301-2429
Dylan E O'SullivanDepartment of Public Health Sciences, Faculty of Medicine, Queen's University, Kingston, Ontario, Canada.
Emily V HeerDepartment of Cancer Epidemiology and Prevention Research, CancerControl Alberta, Alberta Health Services, Calgary, Alberta, Canada.
Robert J HilsdenDepartment of Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
Tolulope T SajobiDepartment of Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
Winson Y CheungDepartment of Medicine, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
Darren R BrennerDepartment of Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
Christine M FriedenreichDepartment of Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.ORCID 0000-0002-4783-1966

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundFactors that are prognostic of early discontinuation of adjuvant chemotherapy among stage III colon cancer patients have yet to be described. To address this gap, a survey of medical oncologists and a systematic review and meta-analysis were conducted.

methodsA survey was distributed in March 2019 to medical oncologists who treat colon cancer within Alberta, Canada. Clinicians were asked to rank the prognostic importance of a set of variables using a Likert scale and agreement was quantified using a weighted Cohen's kappa. In addition, we systematically searched four databases up to July 2019. Meta-analyses were conducted using a random-effects model.

resultsOf the 25 clinicians who were sent the survey, 14 responded. Overall, there was no agreement regarding which variables were prognostic of early discontinuation (weighted Cohen's kappa = 0.12; 95% CI = 0.05-0.18). From an initial 3927 articles, 18 investigations were identified for inclusion in our review. Based upon evidence from both the survey and the systematic review, the following four variables were identified as being prognostic of early discontinuation: (a) comorbidity (OR

conclusionsCurrent evidence is heterogeneous and limited. Additional research is needed to confirm our findings and to explore additional prognostic factors.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsChemotherapy, AdjuvantColectomyColonic NeoplasmsCross-Sectional StudiesDrug-Related Side Effects and Adverse ReactionsHumansNeoplasm StagingObservational Studies as TopicOncologistsPrognosisRandomized Controlled Trials as TopicRisk AssessmentRisk FactorsSeverity of Illness IndexSurveys and Questionnairesadherenceadjuvant chemotherapycolorectal neoplasmscompletiondiscontinuation

Identifiers

PMID31962372
PMCPMC7050079

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.